Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent

1 Dec 2011

Abstract excerpt

Targeting DNA repair with poly(ADP-ribose) polymerase (PARP) inhibitors has shown a broad range of anti-tumor activity in patients with advanced malignancies with and without BRCA deficiency. It remains unclear what role p53 plays in response to PARP inhibition in BRCA-proficient cancer cells treated with DNA damaging agents. Using gene expression microarray analysis, we find that DNA damage response (DDR)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22101337
DOI: 10.4161/cc.10.23.18170

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agentPMID 22101337Read ↗

A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitorsSemantic proximity Read ↗

Role of PARP Inhibitors in Cancer Biology and TherapySemantic proximity Read ↗

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?Semantic proximity Read ↗

Therapeutic Targeting of DNA Damage Response Pathways in TP53 - and ATM -Mutated TumorsSemantic proximity Read ↗

Current status of poly(ADP-ribose) polymerase inhibitors and future directionsSemantic proximity Read ↗

Profile of veliparib and its potential in the treatment of solid tumorsSemantic proximity Read ↗

New Insights into PARP Inhibitors' Effect on Cell Cycle and Homology-Directed DNA Damage RepairSemantic proximity Read ↗

PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human CellsSemantic proximity Read ↗

A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic LeukemiaSemantic proximity Read ↗

Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.Semantic proximity Read ↗

The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatmentSemantic proximity Read ↗

Expression of Poly (Adenosine Diphosphate-Ribose) Polymerase and p53 in Epithelial Ovarian Cancer and Their Role in Prognosis and Disease OutcomeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.